[Myelodysplastic syndrome--classification, prognosis and therapy]

Area of Science:

• Hematology
• Oncology
• Stem Cell Transplantation

Context:

• Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders.
• Prognostic factors and treatment strategies significantly impact MDS patient outcomes.
• Understanding survival rates and leukemic transformation is crucial for managing MDS.

Purpose:

• To analyze the impact of classification, prognostic factors, and treatment on survival and leukemic transformation in primary myelodysplastic syndrome (MDS).
• To evaluate the effectiveness of stem cell transplantation versus non-transplantation in different MDS risk groups.
• To identify specific MDS subgroups that benefit most from stem cell transplantation.

Summary:

• Patients were classified using FAB criteria and risk-stratified by the International Prognostic Scoring System (IPSS).
• Median survival was significantly shorter for patients with RAEB/RAEB-T and intermediate-II/high IPSS risk compared to RA/RARS and low/intermediate-I risk groups, respectively.
• Stem cell transplantation demonstrated a significant survival benefit for patients with RAEB/RAEB-T and intermediate-II/high risk MDS, but not for RA or low/intermediate-I risk groups.

Impact:

• Confirms the adverse prognostic impact of excess blasts in primary MDS.
• Highlights the significant survival benefit of stem cell transplantation for high-risk MDS patients (RAEB, RAEB-T, intermediate-II, high risk).
• Suggests the need for refined criteria for stem cell transplantation indications in lower-risk MDS subgroups (RA, low, intermediate-I).